MedPath

RESOLVE THERAPEUTICS

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:1
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (80.0%)
Phase 1
1 (20.0%)

A Study of RSLV-132 in Females With Sjögren's Disease

Phase 2
Recruiting
Conditions
Primary Sjögren Syndrome
Interventions
Drug: Placebo
First Posted Date
2024-06-04
Last Posted Date
2025-07-18
Lead Sponsor
Resolve Therapeutics
Target Recruit Count
106
Registration Number
NCT06440525
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Resolve Clinical Site, San Antonio, Texas, United States

🇺🇸

Evolution Research Center, Hialeah, Florida, United States

and more 10 locations

Phase 2 Study of RSLV-132 in Subjects With Long COVID

Phase 2
Completed
Conditions
Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions
First Posted Date
2021-06-29
Last Posted Date
2024-05-29
Lead Sponsor
Resolve Therapeutics
Target Recruit Count
112
Registration Number
NCT04944121
Locations
🇺🇸

Resolve Clinical Center, Seattle, Washington, United States

A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

Phase 2
Completed
Conditions
Sjogren's Syndrome
Interventions
Drug: Placebo
First Posted Date
2017-08-14
Last Posted Date
2021-04-02
Lead Sponsor
Resolve Therapeutics
Target Recruit Count
28
Registration Number
NCT03247686
Locations
🇬🇧

University Hospitals Birmingham, Birmingham, Edgbaston, United Kingdom

🇬🇧

Newcastle upon Tyne Hospitals, Newcastle upon Tyne, Gosforth, United Kingdom

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

Phase 2
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Placebo
First Posted Date
2016-01-21
Last Posted Date
2021-03-10
Lead Sponsor
Resolve Therapeutics
Target Recruit Count
64
Registration Number
NCT02660944
Locations
🇺🇸

TriWest Research Associates, El Cajon, California, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

Valerius Research Center, Los Alamitos, California, United States

and more 13 locations

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Phase 1
Completed
Conditions
Systemic Lupus Erythematosus
First Posted Date
2014-07-18
Last Posted Date
2015-12-09
Lead Sponsor
Resolve Therapeutics
Target Recruit Count
32
Registration Number
NCT02194400
Locations
🇺🇸

Clinical Research of West Florida, Clearwater, Florida, United States

🇺🇸

West Michigan Rheumatology, Grand Rapids, Michigan, United States

🇺🇸

Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.